Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate

Integrative Cancer Therapies

Volumn 6, Issue 4, 2007, Pages 389-399

  Thejass, P ^a   Kuttan, Girija ^a  

^a AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

Allyl isothiocyanate; Angiogenesis; Human umbilical vein endothelial cells; Phenyl isothiocyanate; Proinflammatory cytokines; Vascular endothelial growth factor

Indexed keywords

ALLYL ISOTHIOCYANATE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHENYL ISOTHIOCYANATE; THYMIDINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRITIUM; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKINS; ISOTHIOCYANATES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36249018903     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735407309084     Document Type: Article

References (49)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000 ; 6: 389-395.
2. Ferrara N., Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999 ; 5: 1359-1364.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995 ; 1: 27-31.
4. Nyberg P., Xie L., Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005 ; 65: 3968-3979.
5. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1993 ; 103: 1231-1236.
6. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996 ; 86: 353-364.
7. Ribatti D., Vacca A., Dammacco F. The role of vascular phase in solid tumor growth: a historical review. Neoplasia. 1999 ; 1: 293-302.
8. Carmeliet P., Jain RK Angiogenesis in cancer and other diseases. Nature. 2000 ; 407: 249-257.
9. Brien SE, Zagzag D., Brem S. Rapid in situ cellular kinetics of intracerebral tumor angiogenesis using a monoclonal antibody to bromodeoxyuridine. Neurosurgery. 1989 ; 25: 715-719.
10. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer. 2002 ; 2: 83-90.
11. St Croix B., Rago C., Velculescu V., et al. Gene expressed in human tumor endothelium. Science. 2000 ; 289: 1197-1202.
12. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999 ; 77: 527-543.
13. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor and its receptors. FASEB J. 1999 ; 13: 9-22.
14. Nor JE, Christensen J., Mooney DJ, Polverini PJ Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol. 1999 ; 154: 375-384.
15. Hiratsuka S., Nakamura K., Iwai S., et al. MMP-9 induction by vascular endothelial growth factor receptor 1 is involved in lung-specific metastasis. Cancer Cell. 2002 ; 2: 289-300.
16. Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000 ; 2: 737-744.
17. Nelson AR, Fingleton B., Rothenberg ML, Matrisian LM Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000 ; 18: 1135-1149.
18. Docherty AJ, Lyons A., Smith BJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid potentiating activity. Nature. 1985 ; 318: 66-69.
19. Chen Z., Malhotra PS, Thoma GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999 ; 5: 1369-1379.
20. Tookey HL, Van Etten CH, Daxenbichler ME Glucosinolates. In: Liener IE, ed., Toxic Constituents of Plant Foodstuffs. New York, NY: Academic Press ; 1980: 103-142.
21. Zhang Y., Talalay P. Anticarcinogenic action of organic isothiocyanates: chemistry and mechanisms. Cancer Res. 1994 ; 54 (suppl): 1976s - 1981s.
22. Hecht SS Chemoprevention by isothiocyanates. J Cell Biochem. 1995 ; 22: 195-209.
23. Suh SJ, Moon SK, Kim CH Raphanus sativus and its isothiocyanates inhibit vascular smooth muscle cells proliferation and induce G(1) cell cycle arrest. Int Immunopharmacol. 2006 ; 6: 854-861.
24. Wattenberg LW Inhibitory effect of benzyl isothiocyanates administered shortly before diethyl nitrosamine or benzo (a)pyrene on pulmonary and forestomach neoplasia in A/J mice. Carcinogenesis. 1987 ; 12: 1971-1973.
25. Boggards JJP, Van Ommen B., Falke HE, Willems MI, van Bladeren PJ Glutathione S-transferase subunit induction patterns of brussels sprouts, allyl isothiocyanate and goitrin in rat liver and small intestinal mucosa: a new approach for the identification of inducing xenobiotics. Food Chem Toxicol. 1990 ; 28: 81-88.
26. Manesh C., Kuttan G. Effect of naturally occurring allyl and phenyl isothiocyanates in the inhibition of experimental pulmonary metastasis induced by B16F-10 melanoma cells. Fitoterapia. 2003 ; 71: 355-363.
27. Jaffe EA, Nachman RL, Becker CG, Minick CR Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973 ; 52: 2745-2756.
28. Cole SPC. Rapid chemosensitivity testing of human lung tumor cells using MTT assay. Cancer Chemother Pharmacol. 1986 ; 17: 259-263.
29. Guo HB, Lee I., Kamar M., Akiyama SK, Pierce M. Abberant N-glycosylation of β1integrin causes reduced α5β1integrin clustering and stimulates cell migration. Cancer Res. 2002 ; 62: 6837-6845.
30. Albini A., Iwamoto HK, Kleinman GR, et al. A rapid in vitro assay quantitating the invasive potential of tumor cells. Cancer Res. 1987 ; 47: 3239-3245.
31. Gupta K., Kshirsagar S., Chang L., et al. Morphine stimulates angiogenesis by activating proangiogenic and survival promoting signaling and promotes breast tumor growth. Cancer Res. 2002 ; 62: 4491-4498.
32. Leyon PV, Kuttan G. Effect of Tinospora cordifolia on the cytokine profile of angiogenesis-induced animals. Int Immunopharmacol. 2004 ; 4: 1569-1575.
33. Sunila ES, Kuttan G. Piper longum inhibits VEGF and proinflammatory cytokines and tumor induced angiogenesis in C57BL/6 mice. Int Immunopharmacol. 2006 ; 6: 733-741.
34. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000 ; 6: 389-395.
35. Relf M., Jeune LS, Scott PA, et al. Expression of the angiogenic factors-vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997 ; 57 ; 963-969.
36. Coultas L., Chawengsaksophak K., Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005 ; 438: 937-945.
37. Hellwig-Burgel T., Rutkowski K., Metzen E., Fandrey J., Jelkmann W. Interleukin 1β and tumor necrosis factor-α stimulate DNA binding of hypoxia inducible factor-1. Blood. 1999 ; 94: 1561-1567.
38. Jung YJ, Isaacs JS, Sunmin L., Trepel J., Neckers L. IL-1β mediated upregulation of HIF 1α via an NF-κB/cox-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003 ; 17: 2115-2117.
39. Li J., Perrella MA, Tsai JC, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells. J Biol Chem. 1995 ; 270: 308-312.
40. Cohen T., Nahari D., Cerem LW, Neufeld G., Levi BZ Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996 ; 271: 736-741.
41. Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT 3 pathway. Oncogene. 2003 ; 22: 1517-1527.
42. Tilg H., Dinarello CA, Mier JW IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today. 1997 ; 18: 428-432.
43. Bussolino F., Ziche M., Wang J., et al. In vitro and in vivo activation of endothelial cells by colony stimulating factors. J Clin Invest. 1991 ; 87: 986-995.
44. Neville ME, Robb J., Popescu MC In situ vaccination against a non-immunogenic tumor using intratumoral injection of liposomal interleukin-2. Cytokine. 2001 ; 16: 239-250.
45. Caligiuri MA, Murray C., Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2. J Clin Invest. 1993 ; 91: 123-132.
46. Stamenkovic I. Extra cellular matrix remodeling: the role of matrix metalloproteinases. J Pathol. 2003 ; 200: 448-464.
47. Albini A. Tumor and endothelial cell invasion of basement membranes: the matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res. 1998 ; 4: 230-241.
48. Jiang Y., Goldberg ID, Shi YE Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002 ; 21: 2245-2252.
49. Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol. 1993 ; 156: 234-246.